DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

Background Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet. Methods B16 and MC38 tumor cell lines were inoculated subcutaneously into wild-type (WT) and DNGR-1-deficient mice. To overexpress Flt3L systemically, we performed gene therapy through the hydrodynamic injection of an Flt3L-encoding plasmid. To characterize the immune response, we performed flow cytometry and RNA-Seq of tumor-infiltrating cDC1s. Results Here, we found that cross-presentation of tumor antigens in the steady state was DNGR-1-independent. However, on Flt3L systemic overexpression, tumor growth was delayed in DNGR-1-deficient mice compared with WT mice. Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. Mechanistically, the deficiency in DNGR-1 boosted an Flt3L-induced specific inflammatory gene signature in cDC1s, including Ccl5 expression. Indeed, the increased infiltration of cDC1s within tumors and their protective effect rely on CCL5/CCR5 chemoattraction. Moreover, FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer. Notably, cyclophosphamide elevated serum Flt3L levels and, in combination with the absence of DNGR-1, synergized against tumor growth. Conclusion DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression.

[1]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[2]  M. Merad,et al.  β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. , 2019, Cancer discovery.

[3]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[4]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[5]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[6]  M. Diamond,et al.  WDFY4 is required for cross-presentation in response to viral and tumor antigens , 2018, Science.

[7]  A. Planas,et al.  DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment , 2018, Science.

[8]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[9]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[10]  L. Zitvogel,et al.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics , 2017, Oncoimmunology.

[11]  M. Albert,et al.  Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity , 2017, The Journal of experimental medicine.

[12]  I. Melero,et al.  Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells , 2017, Nature Communications.

[13]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[14]  Peisheng Zhang,et al.  Resident memory T cells in the skin mediate durable immunity to melanoma , 2017, Science Immunology.

[15]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[16]  C. del Fresno,et al.  Optimal Generation of Tissue-Resident but Not Circulating Memory T Cells during Viral Infection Requires Crosspriming by DNGR-1+ Dendritic Cells. , 2016, Immunity.

[17]  R. Reguera,et al.  Leishmania Uses Mincle to Target an Inhibitory ITAM Signaling Pathway in Dendritic Cells that Dampens Adaptive Immunity to Infection. , 2016, Immunity.

[18]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[19]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[20]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.

[21]  María Martínez-López,et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.

[22]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[23]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[24]  D. Sancho,et al.  Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice , 2014, European journal of immunology.

[25]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[26]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[27]  P. Bruhns,et al.  Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. , 2014, The Journal of clinical investigation.

[28]  Shamim A. Mollah,et al.  Classical Flt3L-dependent dendritic cells control immunity to protein vaccine , 2014, The Journal of experimental medicine.

[29]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[30]  S. Zelenay,et al.  Genetic Tracing via DNGR-1 Expression History Defines Dendritic Cells as a Hematopoietic Lineage , 2013, Cell.

[31]  J. Blanco,et al.  Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model , 2013, PloS one.

[32]  L. Akslen,et al.  Tumor Necrosis Is a Prognostic Factor in Thick Cutaneous Melanoma , 2012, The American journal of surgical pathology.

[33]  Ansuman T. Satpathy,et al.  Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination , 2012, Proceedings of the National Academy of Sciences.

[34]  Daigo Hashimoto,et al.  Deciphering the transcriptional network of the DC lineage , 2012, Nature Immunology.

[35]  Anna M. Keller,et al.  The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. , 2012, The Journal of clinical investigation.

[36]  M. Wright,et al.  The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. , 2012, Immunity.

[37]  B. Thompson,et al.  F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. , 2012, Immunity.

[38]  Anna M. Keller,et al.  Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.

[39]  F. Ginhoux,et al.  The origin and development of nonlymphoid tissue CD103+ DCs , 2009, The Journal of experimental medicine.

[40]  M. Manz,et al.  The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. , 2009, Blood.

[41]  N. Hacohen,et al.  The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. , 2009, Immunity.

[42]  Anna M. Keller,et al.  Identification of a dendritic cell receptor that couples sensing of necrosis to immunity , 2009, Nature.

[43]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[44]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[45]  Michael S Saag,et al.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.

[46]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Gratwohl,et al.  Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. , 1996, Blood.

[48]  E. Maraskovsky,et al.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.